Compare Navan Inc. Class A Common Stock (NAVN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navan Inc. Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Navan Inc. Class A Common Stock trades at $23.63 (market cap $6.01B), while State Street SPDR S&P Biotech ETF trades at $153.72 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 2,990,425). Which is the better fit depends on your goals — on Pluang, investors hold Navan Inc. Class A Common Stock for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NAVN | XBI | |
|---|---|---|
Market Cap | $6.01B | $10.11B |
Volume | 2,990,425 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $30.58 | $169.55 |
52-Week Low | $8.51 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $5.36B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
